Medicare Part D coverage · entecavir · RxCUI 578457
entecavir 0.5 MG Oral Tablet [Baraclude]
Per the CMS 2026 Part D formulary file, entecavir 0.5 MG Oral Tablet [Baraclude] is covered by 8 Medicare Part D plans (0.2% of enrollable products), averaging Tier 3, with prior authorization required on 50% of covering formularies.
- 0.2%
- Plan coverage
- 8
- Plans covering
- T3
- Avg tier
- 50%
- Prior auth required
What the CMS Formulary Data Shows for entecavir 0.5 MG Oral Tablet [Baraclude]
Per the CMS 2026 Part D formulary file, entecavir 0.5 MG Oral Tablet [Baraclude] (RxNorm concept RXCUI 578457, generic name entecavir) appears on 2 distinct formulary files spanning 8 Medicare Part D plan offerings - 0.2% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 3.
Real-world access to entecavir 0.5 MG Oral Tablet [Baraclude] depends on utilization management as much as tier placement: 50% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 23,172 Part D beneficiaries filled entecavir 0.5 MG Oral Tablet [Baraclude] in 2023, with total plan-and-beneficiary spending of $34,547,603 and an average per-beneficiary annual cost of $1,490.92. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry entecavir 0.5 MG Oral Tablet [Baraclude] today.
Coverage Details
- Formularies covering
- 2
- Plans covering
- 8
- Coverage rate
- 0.2%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 50% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 23,172
- Total spending
- $34,547,603
- Avg per beneficiary
- $1,490.92
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering entecavir 0.5 MG Oral Tablet [Baraclude]
8 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Hamaspik Medicare Choice (HMO D-SNP) | Hamaspik, Inc. | T1 | No | $0 | NY |
| Hamaspik Medicare Select (HMO D-SNP) | Hamaspik, Inc. | T1 | No | $34.50 | NY |
| Óptimo Plus (PPO) | Triple S Advantage, Inc. | T5 | Yes | $0 | PR |
| Contigo Plus (HMO C-SNP) | Triple S Advantage, Inc. | T5 | Yes | $0 | PR |
| Brillante (HMO-POS) | Triple S Advantage, Inc. | T5 | Yes | $0 | PR |
| Enlace Plus (HMO) | Triple S Advantage, Inc. | T5 | Yes | $0 | PR |
| ContigoEnMente (HMO C-SNP) | Triple S Advantage, Inc. | T5 | Yes | $0 | PR |
| Ahorro Plus (HMO) | Triple S Advantage, Inc. | T5 | Yes | $0 | PR |
Frequently Asked Questions
Is entecavir 0.5 MG Oral Tablet [Baraclude] covered by Medicare Part D?
Yes, entecavir 0.5 MG Oral Tablet [Baraclude] is covered by 8 Medicare Part D plans (0.2% of all Part D formularies).
What tier is entecavir 0.5 MG Oral Tablet [Baraclude] on Medicare Part D plans?
entecavir 0.5 MG Oral Tablet [Baraclude] averages Tier 3 across Part D plans, ranging from Tier 1 to Tier 5.
Does entecavir 0.5 MG Oral Tablet [Baraclude] require prior authorization?
50% of Part D formularies require prior authorization for entecavir 0.5 MG Oral Tablet [Baraclude]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on entecavir 0.5 MG Oral Tablet [Baraclude]?
In 2023, total Medicare Part D spending on entecavir 0.5 MG Oral Tablet [Baraclude] was $34,547,603, covering 23,172 beneficiaries. The average spend per beneficiary was $1,490.92.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
Similar prior-authorization rate
- memantine hydrochloride 10 MG Oral Tablet 50% PA
- 0.2 ML adalimumab-atto 50 MG/ML Prefilled Syringe [Amjevita] 50% PA
- prednisolone 15 MG Disintegrating Oral Tablet [Orapred] 50% PA
- trazodone hydrochloride 10 MG/ML Oral Solution [Raldesy] 50% PA
- acetaminophen 325 MG / butalbital 50 MG Oral Tablet [Tencon] 50% PA
- methylprednisolone 8 MG Oral Tablet [Medrol] 50% PA